TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27825007
Drug: Tailored dose-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored dose-dense chemotherapy (4 cycles of leukocyte nadir-based tailored and dose-dense epirubicin and cyclophosphamide every 2 weeks followed by 4 cycles of tailored dose-dense docetaxel every 2 weeks)
Study: 27825007
Drug: Standard 3-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 3-weekly chemotherapy (3 cycles of fluorouracil and epirubicin-cyclophosphamide every 3 weeks followed by 3 cycles of docetaxel every 3 weeks)
Study: 24423358
Drug: TSH-suppressive L-T4
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TSH-suppressive L-T4 doses
Study: 24423358
Drug: Replacement L-T4
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Replacement L-T4 doses
Study: 20686332
Drug: Sulbactomax (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulbactomax (1.5 g)
Study: 12426862
Drug: Alfuzosin, doxazosin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin, doxazosin, tamsulosin, terazosin (α1‐adrenoceptor antagonists)
Study: 12426862
Drug: Lower dosing
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dosing regimen of α1‐adrenoceptor antagonists
Study: 11015162
Drug: Azithromycin, 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin, 1200 mg once weekly (n = 321)
Study: 1360557
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg daily + sotalol
Study: 2865914
Drug: Epidural fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epidural fentanyl (50 μg)
Study: 18093108
Drug: High medication
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High medication guideline adherence
Study: 16239318
Drug: Flu‐Met plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flu‐Met plus oral contraceptive
Study: 16239318
Drug: Flu‐Met plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flu‐Met plus transdermal contraceptive
Study: 12672915
Drug: Egg (640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg (640 mg/d additional dietary cholesterol)
Study: 12672915
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg/d additional dietary cholesterol)
Study: 3946247
Drug: pindolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: pindolol (10 or 20 mg daily) and hydrochlorothiazide (50 mg daily)
Study: 30497467
Drug: Methadone Maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone Maintenance Treatment Programme (MMTP)
Study: 26731696
Drug: Norfloxacin 800
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norfloxacin 800 mg/day for 10 days
Study: 20942646
Drug: RG7128 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7128 monotherapy for 2 weeks (1500 mg twice daily)
Study: 20942646
Drug: RG7128 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG7128 in combination with SOC for 4 weeks (1000 mg and 1500 mg twice daily)
Study: 18806709
Drug: Probiotics (PBs)
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (PBs) administration
Study: 14558182
Drug: Medication advice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication advice and reviews by specialists in clinical pharmacology and cardiology.
Study: 10906167
Drug: Internal medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal medicine service (n = 105)
Study: 10906167
Drug: Internal medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal medicine service
Study: 2566321
Drug: Celiprolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (400 mg)
Study: 31126278
Drug: ACTI-BREAK intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTI-BREAK intervention (3 x 5-minute moderate-intensity breaks daily)
Study: 20632097
Drug: Live View
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live View Video Capsule Endoscopy (VCE)
Study: 19056590
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g whole egg protein
Study: 19056590
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g whole egg protein
Study: 19056590
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g whole egg protein
Study: 19056590
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g whole egg protein
Study: 19056590
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g whole egg protein
Study: 11799544
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy and physician advice
Study: 7756587
Drug: Cytotoxic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotoxic agents (cyclophosphamide or chlorambucil)
Study: 7756587
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment or corticosteroids (control group)
Study: 2111195
Drug: Nitrogen intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrogen intake of 0.2 g kg body-weight-1 24 h-1
Study: 2111195
Drug: Nitrogen intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrogen intake of 0.3 g kg body-weight-1 24 h-1
Study: 2111195
Drug: Nitrogen intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrogen intake of 0.1 g kg body-weight-1 24 h-1
Study: 2111195
Drug: Nitrogen intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrogen intake of 0.0 g kg body-weight-1 24 h-1
Study: 761953
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg nomifensine
Study: 761953
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg racemic amphetamine
Study: 30964707
Drug: Rosiglitazone (PPARγ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (PPARγ agonist)
Study: 6126901
Drug: Haloperidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (1 mg)
Study: 16516824
Drug: Chlorpromazine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpromazine (10 mg)
Study: 16516824
Drug: Nalbuphine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (5 mg, intravenous)
Study: 16516824
Drug: Nalbuphine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (5 mg, intravenous) with neuroleptics
Study: 10740150
Drug: Intravenous felodipine
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous felodipine 0.3 mg
Study: 10740150
Drug: Oral felodipine
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral felodipine 10 mg
Study: 2006757
Drug: bezafibrate 400
Normalized name: bezafibrate 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate 400 mg/day
Study: 2006757
Drug: simvastatin 10-40
Normalized name: ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: simvastatin 10-40 mg/day
Study: 6128281
Drug: Tiopronin 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiopronin 600 mg daily
Study: 29414980
Drug: Pre-treatment costs
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment costs incurred by patients
Study: 29414980
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to treatment initiation
Study: 27168361
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg V116517
Study: 27168361
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg celecoxib
Study: 12111113
Drug: Oral topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral topotecan (2.3 mg/m(2))
Study: 12111113
Drug: Intravenous topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous topotecan (1.5 mg/m(2))
Study: 6627825
Drug: Gentamicin (1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (1.7 mg/kg as a 20‐min infusion every 8 hr for 10 days)
Study: 6627825
Drug: Netilmicin (1.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin (1.7 mg/kg as a 20‐min infusion every 8 hr for 10 days)
Study: 29671128
Drug: Intranasal doxylamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal doxylamine succinate 3.2 mg
Study: 29671128
Drug: Intranasal doxylamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal doxylamine succinate 6.3 mg
Study: 29671128
Drug: Intranasal doxylamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal doxylamine succinate 12.7 mg
Study: 29671128
Drug: Doxylamine succinate
Normalized name: Doxylamine Succinate
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxylamine succinate 25 mg oral tablet
Study: 29671128
Drug: Intranasal doxylamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal doxylamine (all doses)
Study: 25199696
Drug: Epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injection of dexamethasone (2 mL, 8 mg)
Study: 19912273
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement into extraction sockets
Study: 18331601
Drug: CHOP (doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP (doxorubicin 50 mg/m2)
Study: 18331601
Drug: CNOP (mitoxantrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNOP (mitoxantrone 10-12 mg/m2)
Study: 14634144
Drug: Oral estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estriol treatment
Study: 10680109
Drug: Epidural ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural ketamine (0.2 mg/kg)
Study: 10680109
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (2 mg epidural morphine)
Study: 1768504
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three agents (D, M, S)
Study: 31845587
Drug: Valproate with
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate with 24 weeks of atypical antipsychotic
Study: 31845587
Drug: Lithium with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium with 24 weeks of atypical antipsychotic
Study: 31499383
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg/m2/d for 14 days
Study: 31499383
Drug: Dexamethasone 6
Normalized name: dexamethasone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 6 mg/m2/d for 28 days (standard dosing)
Study: 27063678
Drug: Volunteer support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteer support for self-managed computerised aphasia treatment
Study: 9588664
Drug: Trimetazidine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (60 mg orally)
Study: 8026027
Drug: lovastatin 80
Normalized name: fluvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin 80 mg/d
Study: 21190985
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg twice daily lorcaserin
Study: 15730351
Drug: Tiagabine 20
Normalized name: tiaGABine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine 20 mg
Study: 1618109
Drug: Fluorouracil (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil (400 mg/m2 daily for 5 days)
Study: 1618109
Drug: Fluorouracil combined
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil combined with folic acid (100 mg/m2 before each dose of fluorouracil)
Study: 6324332
Drug: Ranitidine tablets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine tablets, 150 mg twice daily
Study: 31187447
Drug: Bergamot oil
Normalized name: Bergamot Oil
DrugBank: Bergamot oil (DB14335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bergamot oil nanospanlastics combined with PUVB therapy
Study: 26547718
Drug: Revised version
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Revised version of the FDA Drug Safety Communication (DSC)
Study: 26547718
Drug: Standard version
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard version of the FDA Drug Safety Communication (DSC)
Study: 26547718
Drug: Both versions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both versions of the FDA Drug Safety Communication (DSC)
Study: 24740826
Drug: Epirubicin/cyclophosphamide (EC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin/cyclophosphamide (EC, 90/600 mg/m2 q3w) followed by docetaxel (D, 100 mg/m2 q3w) with bevacizumab (B, 15 mg/kg q3w)
Study: 24740826
Drug: Epirubicin/cyclophosphamide (EC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin/cyclophosphamide (EC, 90/600 mg/m2 q3w) followed by docetaxel (D, 100 mg/m2 q3w) without bevacizumab
Study: 20404353
Drug: High-dose vigabatrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vigabatrin (100-148 mg/kg/d)
Study: 20404353
Drug: Low-dose vigabatrin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vigabatrin (18-36 mg/kg/d)
Study: 28933338
Drug: 24 µg
Normalized name: penicillin G 24 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 µg of lubiprostone 30 minutes prior to the study
Study: 28933338
Drug: 24 µg
Normalized name: penicillin G 24 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 µg of lubiprostone plus 10 mg of domperidone 30 minutes prior to the study
Study: 11061253
Drug: Riluzole 100
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riluzole 100 mg/day
Study: 11061253
Drug: Riluzole 200
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riluzole 200 mg/day
Study: 9359740
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated Japanese encephalitis vaccine (SA14-14-2)
Study: 26617202
Drug: S-1 (40-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (40-60 mg twice daily for 28 consecutive days, followed by a 14-day break)
Study: 26617202
Drug: Taxane (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane (docetaxel 60-75 mg/m2 at intervals of 3-4 weeks; paclitaxel 80-100 mg/m2 weekly for 3 of 4 weeks; or paclitaxel 175 mg/m2 at intervals of 3-4 weeks)
Study: 22898443
Drug: Symptom-triggered treatment
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom-triggered treatment protocol
Study: 19664302
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (260 mg DHA + 60 mg EPA per g) at doses of 2 g/d
Study: 19664302
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (260 mg DHA + 60 mg EPA per g) at doses of 4 g/d
Study: 19664302
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (260 mg DHA + 60 mg EPA per g) at doses of 6 g/d
Study: 19664302
Drug: Sunola oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunola oil (control; 6 g/d)
Study: 18678802
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (n = 33)
Study: 15358441
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oral estradiol (E(2)) continuously during two 28‐day cycles
Study: 15358441
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oral estradiol (E(2)) continuously during two 28‐day cycles + 800 mg of vaginal progesterone
Study: 15358441
Drug: Intravenous pregnanolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pregnanolone (3alpha‐hydroxy‐5beta‐pregnan‐20‐one)
Study: 28072459
Drug: Motivational interviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational interviewing integrated with cognitive behavioral therapy (MI-CBT)
Study: 24366622
Drug: Plasma homocysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma homocysteine increase of 5.0 μmol/l
Study: 23167181
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus antifungal therapy during operation and postoperation
Study: 19419318
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prevalent vertebral fracture and FRAX with FN BMD
Study: 9412659
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (n = 5)
Study: 9412659
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine (n = 6)
Study: 8505824
Drug: Perioperative total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative total parenteral nutrition (TPN)
Study: 3325316
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg fentiazac twice daily for 3 weeks
Study: 3325316
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg diclofenac sodium twice daily for 3 weeks
Study: 23378398
Drug: Glutamine/amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine/amino acid solution
Study: 12544740
Drug: 10 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL/kg fresh frozen plasma
Study: 9792579
Drug: Budesonide forte
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide forte (1,200 mg/d) for 6 weeks
Study: 7707113
Drug: Concurrent radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent radiotherapy and chemotherapy (vindesine 3 mg/m2 on days 1, 8, 29, and 36; cisplatin 100 mg/m2 on days 1 and 29; mitomycin 8 mg/m2 on days 1 and 29; radiotherapy for 3 weeks with 2 Gy given 13 times)
Study: 2540136
Drug: Trimethoprim-polymyxin B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-polymyxin B sulphate ophthalmic ointment, four times a day for seven days (in three studies) and three times a day for five days (in one study)
Study: 2540136
Drug: Chloramphenicol ophthalmic
Normalized name: chloramphenicol ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol ophthalmic ointment, four times a day for seven days (in three studies) and three times a day for five days (in one study)
Study: 30810254
Drug: Dapagliflozin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (5 mg/d for 24 weeks)
Study: 27703067
Drug: 8% Papain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8% Papain gel
Study: 27703067
Drug: Carbopol gel
Normalized name: Carbopol 981
DrugBank: Carbomer (DB15649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbopol gel (control)
Study: 24314186
Drug: Propranolol (2‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (2‐3 mg/kg/d)
Study: 24314186
Drug: Prednisolone (1‐4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (1‐4 mg/kg/d)
Study: 21677329
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 1,200 mg
Study: 19555621
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metoclopramide administered as a 2-minute bolus (BG)
Study: 19555621
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metoclopramide administered as a slow infusion for 15 minutes (IG)
Study: 15304173
Drug: Complete distal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete distal aortic occlusion (</=60 min, with heparin and protamine reversal)
Study: 31994476
Drug: Cannabidiol (CBD),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidiol (CBD), 600 mg, orally administered
Study: 31301615
Drug: bupropion XL
Normalized name: Bupropion Hydrochloride 150 MG Oral Tablet, Extended Release [BUPROPION XL]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupropion XL 150 mg, 300 mg, 300 mg (once-daily)
Study: 31301615
Drug: escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: escitalopram 10 mg, 10 mg, 10-20 mg (once-daily)
Study: 29037805
Drug: Olaparib capsules
Normalized name: Olaparib Capsules
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib capsules (400 mg PO b.i.d.)
Study: 23736824
Drug: Single‐injection ipsilateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single‐injection ipsilateral interscalene brachial plexus block
Study: 21442813
Drug: Hour-prescription of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hour-prescription of points (acupoints of Spleen Meridian selected from 10:04 a.m. to 12:04 a.m.)
Study: 17870419
Drug: Chiropractic manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic manual therapy only
Study: 17870419
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy followed by exercise
Study: 15318306
Drug: Radionuclide methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radionuclide methods (99mTc‐diethyl‐IDA injection, 360 MBq)
Study: 11403533
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of proton pump inhibitors twice daily with H2-receptor antagonist at bedtime
Study: 8041415
Drug: Protracted infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Protracted infusion of fluorouracil during pelvic irradiation
Study: 8041415
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of systemic fluorouracil alone
Study: 3052971
Drug: Graduated progressive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graduated progressive training (aerobic conditioning and strength exercises) performed twice weekly for 8 weeks
Study: 29630516
Drug: Basic body
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic body awareness therapy (BBAT)